Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
Related to this article
The GOBLET trial showed durability in patients with previously treated squamous cell anal carcinoma.
ESMO 2026 unveils GI cancer advances: targeted and immunotherapy regimens boost survival in pancreatic, colorectal, gastric, and HER2+ gastroesophageal disease.
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
2
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
UGN-101 Shows Durable Responses in Urothelial Cancer in 5-Year Follow-Up
5